7-Azaindole Serotonin Agonists With Reduced Hallucinogenic Liability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current psychedelic drugs like psilocybin and LSD are hallucinogenic and cardiotoxic, limiting their widespread use for treating psychological disorders, and there is a need for non-hallucinogenic, non-cardiotoxic compounds that can modulate the 5-HT2A receptor for therapeutic use outside clinical settings.
Innovation Solution
Development of hallucinogenic and non-hallucinogenic serotonin receptor agonist compounds, represented by Formula I, which can be administered daily/weekly without medical supervision, addressing the limitations of existing psychedelic drugs.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If psychedelic drugs like psilocybin and LSD are used to treat psychological disorders, then therapeutic effects are achieved through 5-HT2A receptor modulation, but hallucinogenic effects and cardiotoxicity occur due to strong agonistic effects at 5-HT2B receptor
Solution Approach 1:
The patent applies local quality by introducing specific substitutions at defined positions of the tryptamine core structure. The 7-azaindole analogs feature selective substitution patterns (e.g., methoxy groups at specific positions, alkyl chains of defined lengths) that locally modify receptor interaction properties. This enables differentiation between 5-HT2A and 5-HT2B receptor binding characteristics, achieving therapeutic effect while minimizing cardiotoxicity.
Solution Approach 2:
The patent systematically varies structural parameters of the tryptamine scaffold, including ring substitutions (7-azaindole vs. indole), side chain modifications (alkyl, alkoxy, halo groups), and positional isomers. These parameter changes create a structure-activity relationship framework that identifies compounds with optimized therapeutic windows, separating desired 5-HT2A-mediated effects from harmful 5-HT2B-mediated cardiotoxicity.
2Object-affected harmful factors
If psychedelic-based drug therapies are administered in clinical settings with medical professionals, then safety is improved, but accessibility and ease of operation are reduced
Solution Approach 1:
The patent develops compounds with improved safety profiles that enable single-use or limited-use therapeutic regimens without requiring ongoing clinical supervision. The 7-azaindole analogs are designed to produce sustained therapeutic effects from single administrations, reducing the need for repeated clinic visits and professional oversight while maintaining safety through optimized pharmacological properties.
3Reliability
If tryptamine drugs are developed to maintain strong 5-HT2A receptor agonism for therapeutic effect, then neuroplasticity is promoted, but cardiotoxicity increases due to strong agonistic effects at 5-HT2B receptor
Solution Approach 1:
The patent segments the receptor binding interactions by introducing the 7-azaindole core structure with specific substitution patterns. This segmentation creates distinct binding characteristics for 5-HT2A versus 5-HT2B receptors, allowing strong agonism at 5-HT2A (promoting neuroplasticity) while reducing affinity or agonistic effect at 5-HT2B (minimizing cardiotoxicity).
Data Source
AI summary
Hallucinogenic and non-hallucinogenic serotonin receptor agonists are disclosed herein in addition to methods of making and using the same.